Amedisys Inc - Common Stock (NQ:AMED)

100.99 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amedisys Inc - Common Stock

< Previous 1 2 3 4 5 Next >

Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023 ↗

March 13, 2023

Via Benzinga

What 10 Analyst Ratings Have To Say About Amedisys ↗

March 13, 2023

Via Benzinga

Preview: Amedisys's Earnings ↗

February 14, 2023

Via Benzinga

Where Amedisys Stands With Analysts ↗

February 13, 2023

Via Benzinga

Amedisys Board of Directors Authorizes $100 Million Stock Repurchase Program

February 09, 2023

From Amedisys, Inc.

Via GlobeNewswire

Analyst Ratings for Amedisys ↗

January 19, 2023

Via Benzinga

Expert Ratings for Amedisys ↗

October 27, 2022

Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings:

Via Benzinga

Meta Platforms To Rally 34%? Here Are 10 Other Analyst Forecasts For Thursday ↗

January 05, 2023

Via Benzinga

Amedisys Completes Home Health Joint Venture with the University of Arkansas for Medical Sciences

December 13, 2022

From Amedisys, Inc.

Via GlobeNewswire

Amedisys is Named One of the Most Responsible Companies of 2023 by Statista and Newsweek

December 08, 2022

From Amedisys, Inc.

Via GlobeNewswire

Amedisys Names Scott Ginn Acting Chief Operating Officer

November 22, 2022

From Amedisys, Inc.

Via GlobeNewswire

Expert Ratings for Amedisys ↗

October 24, 2022

Amedisys (NASDAQ:AMED) has observed the following analyst ratings within the last quarter:

Via Benzinga

Where Amedisys Stands With Analysts ↗

October 24, 2022

Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter:

Via Benzinga

Amedisys Statement on CY 2023 Home Health Final Rule

November 01, 2022

From Amedisys, Inc.

Via GlobeNewswire

Mastercard To $428? Plus This Analyst Slashes PT On Intel ↗

October 31, 2022

Barclays cut the price target on Mastercard Incorporated (NYSE: MA) from $430 to $428. Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. Mastercard shares fell 0.6% to...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022 ↗

October 27, 2022

Upgrades

Via Benzinga

6 Analysts Have This to Say About Amedisys ↗

October 03, 2022

Amedisys (NASDAQ:AMED) has observed the following analyst ratings within the last quarter:

Via Benzinga

Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday ↗

October 28, 2022

Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

October 27, 2022

On Thursday, 111 stocks hit new 52-week lows.

Via Benzinga

Why UserTesting Shares Are Trading Higher By Around 93%? Here Are 53 Stocks Moving In Thursday's Mid-Day Session ↗

October 27, 2022

Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) gained 111% to $2.03 after the company announced it entered into a license agreement with Transcosmos Digital Technology for its Apromore process...

Via Benzinga

Credit Suisse, Meta Platforms, Wolfspeed And Some Other Big Stocks Moving Lower On Thursday ↗

October 27, 2022

U.S. stocks traded mixed, with the Dow Jones gaining more than 300 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Amedisys's Return on Invested Capital Overview ↗

October 27, 2022

Pulled from Benzinga Pro data, Amedisys (NASDAQ:AMED) showed a loss in earnings since Q2, totaling $25.40 million. Sales, on the other hand, increased by 0.02% to $557.99 million during Q3.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 27, 2022

Gainers Clearside Biomedical (NASDAQ:CLSD) stock rose 27.3% to $1.35 during Thursday's pre-market session. The market value of their outstanding shares is at $81.2 million.

Via Benzinga

Amedisys: Q3 Earnings Insights ↗

October 26, 2022

Amedisys (NASDAQ:AMED) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amedisys missed estimated...

Via Benzinga

Preview: Amedisys's Earnings ↗

October 25, 2022

Amedisys (NASDAQ:AMED) is set to give its latest quarterly earnings report on Wednesday, 2022-10-26. Here's what investors need to know before the announcement. Analysts estimate that Amedisys will...

Via Benzinga

University of Arkansas for Medical Sciences (UAMS) Announces a Partnership with Amedisys and Contessa, Creating a Comprehensive Care at Home Suite of Services

October 11, 2022

From Amedisys, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022 ↗

August 02, 2022

Upgrades

Via Benzinga

What 9 Analyst Ratings Have To Say About Amedisys ↗

July 28, 2022

Over the past 3 months, 9 analysts have published their opinion on Amedisys (NASDAQ:AMED) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Recap: Amedisys Q2 Earnings ↗

July 27, 2022

Amedisys (NASDAQ:AMED) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amedisys beat estimated earnings by...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2022 ↗

June 29, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.